| 引用本文: |
赫玉芳,沈凯月,张成叶,等.利益相关者视角下中成药集中带量采购政策实施效果的影响研究*[J].中国卫生经济,2023,42(4):16-19.[点击复制] |
HE Yu-fang,SHEN Kai-yue,ZHANG Cheng-ye,et al.A Study on the Impact of the Implementation Effect of Centralized Quantity Procurement Policy for Proprietary Chinese Medicines Based on Stakeholder Perspective[J].CHINESE HEALTH ECONOMICS,2023,42(4):16-19.[点击复制] |
|
| |
|
|
| 本文已被：浏览 1316次 下载 1522次 |
码上扫一扫！ |
| 利益相关者视角下中成药集中带量采购政策实施效果的影响研究* |
| 赫玉芳,沈凯月,张成叶,夏昉 |
|
|
| (长春中医药大学健康管理学院 长春 130117) |
|
| 摘要: |
| 目的：探析我国中成药集中带量采购政策执行状况，为该政策可持续发展提供相应思路。方法：通过梳理政策实施现状，并基于利益相关者视角，探究该政策执行对医保部门、中成药企业、医疗机构、医生及患者产生的效果影响。结果：政策的实施巩固了医保部门在医药行业中的地位，有效缓解医保基金收支压力；中成药企业成本结构得到改善，且行业集中度有所增强；扭转医疗机构和医生的收入结构；患者用药经济负担有所减轻，但其用药多样性需求未得到满足。结论： 制定合理药价区间，不断完善公立医院医生收入激励机制，坚持以质量安全为核心、以民众需求为导向，仍是政策发展的重要方向。 |
| 关键词: 中成药 集中带量采购政策 利益相关者 |
| DOI： |
|
| 基金项目:吉林省中医药管理局中医药政策与发展项目(ZCYFZ-2020-008)；吉林省医药产业创新生态发展模式研究(JJKH20211008SK) |
|
| A Study on the Impact of the Implementation Effect of Centralized Quantity Procurement Policy for Proprietary Chinese Medicines Based on Stakeholder Perspective |
| HE Yu-fang,SHEN Kai-yue,ZHANG Cheng-ye,XIA fang |
| (Changchun University of Traditional Chinese Medicine,Changchun 130117 ,China) |
| Abstract: |
| Objective: To explore the implementation status of China's centralized quantity purchasing policy for proprietary Chinese medicines and provide corresponding ideas for the sustainable development of the policy. Methods: By sorting out the current status of the policy implementation and based on the stakeholder perspective，it explored the effects of the policy implementation on health insurance departments，proprietary Chinese medicine companies，medical institutions and doctors and patients. Results: The implementation of the policy has consolidated the position of the health insurance sector in the pharmaceutical industry，effectively relieved of the pressure on the income and expenditure of the medical insurance fund，improved cost structure of proprietary Chinese medicine companies，increased industry concentration，reversed the revenue structure of medical institutions and physicians，reduced the financial burden of medication use for patients while the need for medication diversity has not been met. Conclusion: Setting a reasonable drug price range，continuously improving the income incentive mechanism for doctors in public hospitals，and adhering to the quality and safety as the core，to the needs of the people as the guide are still important directions for policy development. |
| Key words: traditional Chinese medicines centralized quantity procurement policy stakeholders |
|
|